224 related articles for article (PubMed ID: 22619570)
1. The nicotinic acetylcholine receptor as a target for antidepressant drug development.
Philip NS; Carpenter LL; Tyrka AR; Price LH
ScientificWorldJournal; 2012; 2012():104105. PubMed ID: 22619570
[TBL] [Abstract][Full Text] [Related]
2. The contribution of α4β2 and non-α4β2 nicotinic acetylcholine receptors to the discriminative stimulus effects of nicotine and varenicline in mice.
de Moura FB; McMahon LR
Psychopharmacology (Berl); 2017 Mar; 234(5):781-792. PubMed ID: 28028600
[TBL] [Abstract][Full Text] [Related]
3. The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: differences in α4β2 nicotinic receptor activation.
Cunningham CS; McMahon LR
Eur J Pharmacol; 2011 Mar; 654(1):47-52. PubMed ID: 21172344
[TBL] [Abstract][Full Text] [Related]
4. Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice.
Mineur YS; Somenzi O; Picciotto MR
Neuropharmacology; 2007 Apr; 52(5):1256-62. PubMed ID: 17320916
[TBL] [Abstract][Full Text] [Related]
5. Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors.
Yu LF; Zhang HK; Caldarone BJ; Eaton JB; Lukas RJ; Kozikowski AP
J Med Chem; 2014 Oct; 57(20):8204-23. PubMed ID: 24901260
[TBL] [Abstract][Full Text] [Related]
6. Cytisine-based nicotinic partial agonists as novel antidepressant compounds.
Mineur YS; Eibl C; Young G; Kochevar C; Papke RL; Gündisch D; Picciotto MR
J Pharmacol Exp Ther; 2009 Apr; 329(1):377-86. PubMed ID: 19164465
[TBL] [Abstract][Full Text] [Related]
7. Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists.
Papke RL; Trocmé-Thibierge C; Guendisch D; Al Rubaiy SA; Bloom SA
J Pharmacol Exp Ther; 2011 May; 337(2):367-79. PubMed ID: 21285282
[TBL] [Abstract][Full Text] [Related]
8. Distinctive nicotinic acetylcholine receptor functional phenotypes of rat ventral tegmental area dopaminergic neurons.
Yang K; Hu J; Lucero L; Liu Q; Zheng C; Zhen X; Jin G; Lukas RJ; Wu J
J Physiol; 2009 Jan; 587(2):345-61. PubMed ID: 19047205
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of dopamine, norepinephrine and serotonin release in the rat prefrontal cortex by neuronal nicotinic acetylcholine receptor agonists.
Rao TS; Correa LD; Adams P; Santori EM; Sacaan AI
Brain Res; 2003 Nov; 990(1-2):203-8. PubMed ID: 14568345
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of evoked calcitonin gene-related peptide release from oral mucosa: a potential basis for the pro-inflammatory effects of nicotine.
Dussor GO; Leong AS; Gracia NB; Kilo S; Price TJ; Hargreaves KM; Flores CM
Eur J Neurosci; 2003 Nov; 18(9):2515-26. PubMed ID: 14622152
[TBL] [Abstract][Full Text] [Related]
11. Roles of nicotinic acetylcholine receptor beta subunits in function of human alpha4-containing nicotinic receptors.
Wu J; Liu Q; Yu K; Hu J; Kuo YP; Segerberg M; St John PA; Lukas RJ
J Physiol; 2006 Oct; 576(Pt 1):103-18. PubMed ID: 16825297
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic characterization of a nicotine-discriminative stimulus in rhesus monkeys.
Cunningham CS; Javors MA; McMahon LR
J Pharmacol Exp Ther; 2012 Jun; 341(3):840-9. PubMed ID: 22438471
[TBL] [Abstract][Full Text] [Related]
13. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.
Rollema H; Shrikhande A; Ward KM; Tingley FD; Coe JW; O'Neill BT; Tseng E; Wang EQ; Mather RJ; Hurst RS; Williams KE; de Vries M; Cremers T; Bertrand S; Bertrand D
Br J Pharmacol; 2010 May; 160(2):334-45. PubMed ID: 20331614
[TBL] [Abstract][Full Text] [Related]
14. Differential cross-tolerance to the effects of nicotinic acetylcholine receptor drugs in C57BL/6J mice following chronic varenicline.
de Moura FB; McMahon LR
Behav Pharmacol; 2019 Aug; 30(5):412-421. PubMed ID: 30398980
[TBL] [Abstract][Full Text] [Related]
15. CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation.
Sala M; Braida D; Pucci L; Manfredi I; Marks MJ; Wageman CR; Grady SR; Loi B; Fucile S; Fasoli F; Zoli M; Tasso B; Sparatore F; Clementi F; Gotti C
Br J Pharmacol; 2013 Feb; 168(4):835-49. PubMed ID: 22957729
[TBL] [Abstract][Full Text] [Related]
16. Neuronal Nicotinic Acetylcholine Receptor Modulators Reduce Sugar Intake.
Shariff M; Quik M; Holgate J; Morgan M; Patkar OL; Tam V; Belmer A; Bartlett SE
PLoS One; 2016; 11(3):e0150270. PubMed ID: 27028298
[TBL] [Abstract][Full Text] [Related]
17. Nicotinic receptor partial agonists alter catecholamine homeostasis and response to nicotine in PC12 cells.
Turcanu DS; Kirtok N; Eibl C; Guendisch D; LaGamma EF; Nankova BB
Neurosci Lett; 2012 May; 516(2):212-6. PubMed ID: 22503726
[TBL] [Abstract][Full Text] [Related]
18. Cytisine - From the Past to the Future.
Paduszyńska A; Banach M; Rysz J; Dąbrowa M; Gąsiorek P; Bielecka-Dąbrowa A
Curr Pharm Des; 2018; 24(37):4413-4423. PubMed ID: 30885113
[TBL] [Abstract][Full Text] [Related]
19. Long-term exposure to the new nicotinic antagonist 1,2-bisN-cytisinylethane upregulates nicotinic receptor subtypes of SH-SY5Y human neuroblastoma cells.
Riganti L; Matteoni C; Di Angelantonio S; Nistri A; Gaimarri A; Sparatore F; Canu-Boido C; Clementi F; Gotti C
Br J Pharmacol; 2005 Dec; 146(8):1096-109. PubMed ID: 16273122
[TBL] [Abstract][Full Text] [Related]
20. Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests.
Andreasen JT; Redrobe JP
Behav Brain Res; 2009 Jan; 197(1):150-6. PubMed ID: 18786574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
